Full drug development — from first synthesis of a new chemical entity to FDA approval — costs, on average, $2.6 […]

The FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is the primary trade ledger

The Food and Drug Administration (FDA) Orange Book is the primary financial barrier between a blockbuster drug and its generic

The pharmaceutical market operates as a system of time-limited monopolies where the legal strength of a patent portfolio dictates the

The pharmaceutical industry faces a financial contraction of historic proportions. Between 2025 and 2030, $300 billion in annual prescription drug

The $400 Billion Revenue Precipice The biopharmaceutical sector is entering a period of revenue contraction that threatens the financial stability

The global pharmaceutical industry is currently navigating a pivotal transition characterized by a monumental wave of patent expirations that will

The contemporary pharmaceutical landscape is defined by a paradigm shift in lifecycle management (LCM), moving beyond traditional defensive tactics toward

The global biopharmaceutical industry is undergoing a structural transformation characterized by the convergence of advanced material science, stringent regulatory evolution,